AAP
AKBA icon

Arax Advisory Partners’s Akebia Therapeutics AKBA Stock Holding History

Arax Advisory Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.4K Buy
39,102
+9
+0% +$12 ﹤0.01% 1661
2025
Q4 		$62.9K Sell
39,093
-507
-1% -$1.06K ﹤0.01% 1504
2025
Q3 		$108K Buy
39,600
+14,783
+60% +$49.2K ﹤0.01% 1507
2025
Q2 		$90.3K Hold
24,817
– – ﹤0.01% 977
2025
Q1 		$47.6K Buy
24,817
+11,117
+81% +$22.7K ﹤0.01% 961
2024
Q4 		$26K Buy
+13,700
New +$23.8K ﹤0.01% 1110

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Arax Advisory Partners's AKBA Position: Q1 2026 in Review

Arax Advisory Partners increased its Akebia Therapeutics (AKBA) stake by 0.02% in Q1 2026, buying an estimated $12 and bringing the position to 39,102 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1661.

Arax Advisory Partners first reported a position in AKBA in Q4 2024 and has held it in 6 quarters since. The position peaked at $108K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Arax Advisory Partners held 39,102 shares of Akebia Therapeutics worth $54.4K as of Q1 2026.
  • Arax Advisory Partners bought 9 Akebia Therapeutics shares in Q1 2026, an estimated $12.
  • Akebia Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1661 holding.
  • Arax Advisory Partners first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Akebia Therapeutics position peaked at $108K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.